Antirheumatika

Antirheumatika, commonly referred to as antirheumatic drugs, are medications used to treat rheumatoid arthritis and other forms of inflammatory arthritis. These drugs aim to reduce inflammation, relieve pain, and prevent joint damage, thereby improving mobility and quality of life for affected individuals. The classification of antirheumatic drugs includes both nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs), among others.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed antirheumatic medications. They work by inhibiting the enzyme cyclooxygenase (COX), which plays a key role in the production of prostaglandins—compounds that promote inflammation, pain, and fever. Common NSAIDs include ibuprofen, naproxen, and aspirin. While effective for symptom relief, long-term use of NSAIDs may be associated with side effects such as gastrointestinal irritation, kidney damage, and an increased risk of cardiovascular events.

Disease-modifying antirheumatic drugs (DMARDs) represent a more targeted approach to treating rheumatoid arthritis. Unlike NSAIDs, which primarily alleviate symptoms, DMARDs aim to slow or halt disease progression by suppressing the immune system’s overactive response. Methotrexate is one of the most widely used DMARDs, often prescribed as a first-line therapy. Other DMARDs include leflunomide, sulfasalazine, and hydroxychloroquine. Biologic DMARDs, such as tumor necrosis factor (TNF) inhibitors, are a newer class of drugs that specifically target proteins involved in inflammation, offering high efficacy with fewer systemic side effects.

Corticosteroids, such as prednisone, are another category of antirheumatic medications used in cases of severe inflammation or flare-ups. While potent and fast-acting, corticosteroids are typically reserved for short-term use due to potential side effects, including weight gain, osteoporosis, and increased susceptibility to infections.

The choice of antirheumatic treatment depends on factors such as disease severity, patient response, and individual health considerations. Close monitoring by healthcare professionals is essential to balance therapeutic benefits with potential risks. Emerging research continues to explore novel therapies, including targeted biologics and small-molecule inhibitors, to improve outcomes for individuals with rheumatic diseases.